Principal Financial Group
RVNC

Principal Financial Group’s Revance Therapeutics, Inc. RVNC Stock Holding History

Principal Financial Group’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-18,375
Closed -$47.2K – 2429
2024
Q2 		$47.2K Sell
18,375
-2,489
-12% -$8.5K ﹤0.01% 2290
2024
Q1 		$103K Sell
20,864
-248,854
-92% -$1.47M ﹤0.01% 2272
2023
Q4 		$2.37M Sell
269,718
-693,311
-72% -$5.68M ﹤0.01% 1749
2023
Q3 		$11M Buy
963,029
+342,540
+55% +$6.59M 0.01% 1177
2023
Q2 		$15.7M Buy
620,489
+589,229
+1,885% +$18.4M 0.01% 997
2023
Q1 		$1.01M Sell
31,260
-3,306
-10% -$103K ﹤0.01% 1854
2022
Q4 		$638K Buy
34,566
+15,963
+86% +$365K ﹤0.01% 1924
2022
Q3 		$502K Sell
18,603
-290
-2% -$5.88K ﹤0.01% 1961
2022
Q2 		$261K Buy
18,893
+6,043
+47% +$93K ﹤0.01% 2223
2022
Q1 		$251K Buy
12,850
+913
+8% +$13.8K ﹤0.01% 2285
2021
Q4 		$195K Sell
11,937
-691,506
-98% -$11.5M ﹤0.01% 2372
2021
Q3 		$19.6M Buy
703,443
+24,812
+4% +$708K 0.01% 968
2021
Q2 		$20.1M Buy
678,631
+130,338
+24% +$3.76M 0.01% 967
2021
Q1 		$15.3M Buy
548,293
+114,515
+26% +$3.17M 0.01% 1138
2020
Q4 		$12.3M Sell
433,778
-134,067
-24% -$3.47M 0.01% 1103
2020
Q3 		$14.3M Buy
567,845
+3,087
+0.5% +$80.9K 0.01% 855
2020
Q2 		$13.8M Buy
564,758
+161,601
+40% +$3.19M 0.01% 855
2020
Q1 		$5.97M Sell
403,157
-13,409
-3% -$277K 0.01% 1190
2019
Q4 		$6.76M Buy
416,566
+93,213
+29% +$1.45M 0.01% 1433
2019
Q3 		$4.2M Buy
323,353
+99,788
+45% +$1.22M ﹤0.01% 1572
2019
Q2 		$2.9M Buy
223,565
+109,297
+96% +$1.38M ﹤0.01% 1664
2019
Q1 		$1.8M Buy
114,268
+167
+0.1% +$2.9K ﹤0.01% 1752
2018
Q4 		$2.3M Sell
114,101
-14,043
-11% -$309K ﹤0.01% 1696
2018
Q3 		$3.18M Buy
128,144
+2,236
+2% +$60.8K ﹤0.01% 1700
2018
Q2 		$3.46M Sell
125,908
-112
-0.1% -$3.37K ﹤0.01% 1677
2018
Q1 		$3.88M Sell
126,020
-160
-0.1% -$5.15K ﹤0.01% 1628
2017
Q4 		$4.51M Buy
126,180
+48,121
+62% +$1.38M ﹤0.01% 1598
2017
Q3 		$2.15M Sell
78,059
-3,375
-4% -$81.8K ﹤0.01% 1723
2017
Q2 		$2.15M Buy
81,434
+83
+0.1% +$1.85K ﹤0.01% 1730
2017
Q1 		$1.69M Buy
81,351
+138
+0.2% +$2.83K ﹤0.01% 1744
2016
Q4 		$1.68M Buy
81,213
+861
+1% +$14.4K ﹤0.01% 1742
2016
Q3 		$1.3M Buy
80,352
+385
+0.5% +$5.59K ﹤0.01% 1732
2016
Q2 		$1.09M Sell
79,967
-1,305
-2% -$23.1K ﹤0.01% 1741
2016
Q1 		$1.42M Sell
81,272
-476
-0.6% -$9.69K ﹤0.01% 1683
2015
Q4 		$2.79M Buy
81,748
+3,481
+4% +$121K ﹤0.01% 1561
2015
Q3 		$2.33M Buy
78,267
+1,502
+2% +$45.6K ﹤0.01% 1607
2015
Q2 		$2.46M Buy
76,765
+6,125
+9% +$157K ﹤0.01% 1640
2015
Q1 		$1.46M Sell
70,640
-1,798
-2% -$31.1K ﹤0.01% 1706
2014
Q4 		$1.23M Sell
72,438
-178
-0.2% -$3.11K ﹤0.01% 1768
2014
Q3 		$1.4M Buy
72,616
+5,581
+8% +$145K ﹤0.01% 1719
2014
Q2 		$2.28M Buy
67,035
+7,035
+12% +$220K ﹤0.01% 1656
2014
Q1 		$1.89M Buy
+60,000
New +$1.87M ﹤0.01% 1666

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

Principal Financial Group's RVNC Position: Q3 2024 in Review

Principal Financial Group sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2024, closing a stake of 18,375 shares — an estimated $47.2K sold.

Principal Financial Group first reported a position in RVNC in Q1 2014 and held it in 42 quarters. The position peaked at $20.1M in Q2 2021. 201 funds tracked by Wall St. Rank hold RVNC as of Q3 2024.

  • Principal Financial Group reported no remaining Revance Therapeutics, Inc. position as of Q3 2024 after selling out during the quarter.
  • Principal Financial Group sold 18,375 Revance Therapeutics, Inc. shares in Q3 2024, an estimated $47.2K.
  • Principal Financial Group first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 42 quarters.
  • Principal Financial Group's Revance Therapeutics, Inc. position peaked at $20.1M in Q2 2021.
  • 201 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2024.

Based on Principal Financial Group's 13F filing for Q3 2024, filed 31 Oct 2024.